OPK Stock Overview
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.
OPKO Health Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.24|
|52 Week High||US$6.27|
|52 Week Low||US$3.26|
|1 Month Change||-11.11%|
|3 Month Change||14.91%|
|1 Year Change||-3.86%|
|3 Year Change||11.29%|
|5 Year Change||-51.21%|
|Change since IPO||-5.78%|
Recent News & Updates
OPKO Health (NASDAQ:OPK) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
OPKO Health: Undervalued Opportunity
The company's revenue over the past 12 months amounted to about $1.87 billion, an increase of 30.2% compared to 2020. OPKO Health's net debt was about $95.7 million in Q3 2021, down 60.4% from a year earlier and 48.2% down from Q2 2021. In Q4 2021, OPKO Health, in partnership with Pfizer, received regulatory approval from Australia, Canada for the use of Ngenla (somatrogon). BioReference Laboratories has concluded COVID-19 testing agreements with all major sports organizations, namely NHL, NFL, NBA, MLS. Increase in the volume of genetic testing in Q3 by 19.1% compared to Q3 2020.
|OPK||US Biotechs||US Market|
Return vs Industry: OPK exceeded the US Biotechs industry which returned -22% over the past year.
Return vs Market: OPK underperformed the US Market which returned 4.2% over the past year.
|OPK Average Weekly Movement||8.5%|
|Biotechs Industry Average Movement||10.2%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: OPK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: OPK's weekly volatility (8%) has been stable over the past year.
About the Company
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company’s Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins.
OPKO Health Fundamentals Summary
|OPK fundamental statistics|
Is OPK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OPK income statement (TTM)|
|Cost of Revenue||US$1.29b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.11|
|Net Profit Margin||4.06%|
How did OPK perform over the long term?See historical performance and comparison
Is OPKO Health undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OPK ($4.24) is trading below our estimate of fair value ($22.2)
Significantly Below Fair Value: OPK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OPK is poor value based on its PE Ratio (38x) compared to the US Biotechs industry average (23.1x).
PE vs Market: OPK is poor value based on its PE Ratio (38x) compared to the US market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: OPK is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: OPK is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (1.9x).
How is OPKO Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OPK's forecast earnings growth (35.4% per year) is above the savings rate (2%).
Earnings vs Market: OPK's earnings (35.4% per year) are forecast to grow faster than the US market (12.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: OPK's revenue is expected to decline over the next 3 years (-6.6% per year).
High Growth Revenue: OPK's revenue is forecast to decline over the next 3 years (-6.6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OPK's Return on Equity is forecast to be high in 3 years time
How has OPKO Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OPK has a large one-off gain of $31.1M impacting its September 30 2021 financial results.
Growing Profit Margin: OPK became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: OPK has become profitable over the past 5 years, growing earnings by 13.7% per year.
Accelerating Growth: OPK has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: OPK has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: OPK's Return on Equity (4.3%) is considered low.
How is OPKO Health's financial position?
Financial Position Analysis
Short Term Liabilities: OPK's short term assets ($557.5M) exceed its short term liabilities ($283.0M).
Long Term Liabilities: OPK's short term assets ($557.5M) exceed its long term liabilities ($369.0M).
Debt to Equity History and Analysis
Debt Level: OPK's net debt to equity ratio (3%) is considered satisfactory.
Reducing Debt: OPK's debt to equity ratio has increased from 4.8% to 11.4% over the past 5 years.
Debt Coverage: OPK's debt is well covered by operating cash flow (38.7%).
Interest Coverage: OPK's interest payments on its debt are well covered by EBIT (5x coverage).
What is OPKO Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OPK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OPK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OPK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OPK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OPK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Phil Frost (85 yo)
Dr. Phillip Frost, also known as Phil, M.D., Ph D., has been the Chairman, Chief Executive Officer and Director of OPKO Health, Inc. since March 27, 2007. Dr. Frost serves as the Managing Director and Gene...
CEO Compensation Analysis
Compensation vs Market: Phil's total compensation ($USD1.54M) is below average for companies of similar size in the US market ($USD5.28M).
Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.
Experienced Management: OPK's management team is seasoned and experienced (8.5 years average tenure).
Experienced Board: OPK's board of directors are seasoned and experienced ( 14 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
OPKO Health, Inc.'s employee growth, exchange listings and data sources
- Name: OPKO Health, Inc.
- Ticker: OPK
- Exchange: NasdaqGS
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$2.888b
- Shares outstanding: 681.10m
- Website: https://www.opko.com
Number of Employees
- OPKO Health, Inc.
- 4400 Biscayne Boulevard
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/22 23:26|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.